Based on work studying HB-EGF expression in advanced gastric cancer tumours, it is likely that HB-EGF contributes to the resistance of gastric tumours to trastuzumab- and cetuximab-based therapeutic approaches. The gene discussed is HBEGF; the disease is gastric neoplasm.